Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07508241

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity.

Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects.

The information from this study may help researchers plan future studies of this medicine.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Obesity Body Weight Drug Interaction Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Overweight and/or Obesity Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Pfizer Clinical Research Unit - New Haven

New Haven, Connecticut, 06511, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥18 years at screening, male or female, generally healthy as determined by medical history, physical examination, laboratory tests, and ECG.
  • Body mass index (BMI) 27-45 kg/m² and body weight >50 kg (110 lb).
  • Participants with overweight or obesity

Exclusion criteria

  • History or presence of clinically significant medical conditions, including but not limited to:

--Cardiovascular, hepatic, renal, pulmonary, endocrine, hematologic, neurologic, gastrointestinal (including pancreatitis or gallbladder disease), or significant psychiatric disorders.

  • Any form of diabetes, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dL.
  • Prior exposure to a GLP-1 receptor agonist within 90 days before first dose, or prior participation in a study with PF-08653944.

Treatment and study plan

PF-08653944

Drug

Subcutaneous Injection

Other names: MET097

Acetaminophen

Drug

Oral suspension

Other names: paracetamol

Primary outcomes

  1. Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax)

    Time frame: Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

    To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.

  2. Acetaminophen PK parameters: Area under the plasma concentration (AUC)

    Time frame: Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

    To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.

  3. Acetaminophen PK parameters: Time to Maximum concentration (Tmax)

    Time frame: Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

Secondary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: First dose through study completion, approximately 11 Weeks post last dose.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A PHASE 1, OPEN-LABEL, MULTIPLE DOSE STUDY TO INVESTIGATE THE IMPACT OF PF 08653944 ON GASTRIC EMPTYING IN ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Apr 2, 2026
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.